Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019
Background Response rates of approved systemic therapies for cutaneous T-cell lymphoma (CTCL) hover near 30%, suggesting unmet need. This study describes real-world treatment patterns and response rates of extracorporeal photopheresis (ECP) in CTCL patients.Methods A chart review was conducted in th...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2360568 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846119721255043072 |
|---|---|
| author | Michael Girardi Kacie Carlson Xingyue Huang Shelby L. Corman Patrick Edmundson Jordana Schmier Hrishikesh P. Kale Rutika Raina Francine Foss |
| author_facet | Michael Girardi Kacie Carlson Xingyue Huang Shelby L. Corman Patrick Edmundson Jordana Schmier Hrishikesh P. Kale Rutika Raina Francine Foss |
| author_sort | Michael Girardi |
| collection | DOAJ |
| description | Background Response rates of approved systemic therapies for cutaneous T-cell lymphoma (CTCL) hover near 30%, suggesting unmet need. This study describes real-world treatment patterns and response rates of extracorporeal photopheresis (ECP) in CTCL patients.Methods A chart review was conducted in the United States of adults with CTCL who initiated ECP between January 1, 2017, and February 28, 2019, and received at least three months of ECP treatment as monotherapy or concomitant therapy. Clinical outcomes were collected quarterly for up to 18 months.Results The 52 patients were predominantly Caucasian. Half were male; median age was 69 years. Most patients had Sézary syndrome (50%) or mycosis fungoides (36.5%). Nearly 40% of patients had stage IV disease; 33% had lymph node involvement. Nineteen patients (36.5%) achieved response (>50% reduction in BSA affected); median time to response was 6.5 months. The percentage of patients rated as at least minimally improved was 59.5% at 6 months (N = 22), 75.0% at 9 months (N = 24), and 60.0% at 12 months (N = 15) after ECP initiation.Conclusions Despite the ECP treated population in this study being older and having more advanced-stage disease than recent trials, response rates were comparable. These real-world findings support ECP as an effective treatment option for CTCL patients. |
| format | Article |
| id | doaj-art-b3cd79d46cd3458c9ee543bcfefa74d0 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-b3cd79d46cd3458c9ee543bcfefa74d02024-12-16T22:53:47ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2360568Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019Michael Girardi0Kacie Carlson1Xingyue Huang2Shelby L. Corman3Patrick Edmundson4Jordana Schmier5Hrishikesh P. Kale6Rutika Raina7Francine Foss8Yale School of Medicine, New Haven, Connecticut, USAYale School of Medicine, New Haven, Connecticut, USAMallinckrodt Pharmaceuticals, Bridgewater, New Jersey, USAOPEN Health, Bethesda, Maryland, USAOPEN Health, Bethesda, Maryland, USAOPEN Health, Bethesda, Maryland, USAOPEN Health, Bethesda, Maryland, USAOPEN Health, Bethesda, Maryland, USAYale School of Medicine, New Haven, Connecticut, USABackground Response rates of approved systemic therapies for cutaneous T-cell lymphoma (CTCL) hover near 30%, suggesting unmet need. This study describes real-world treatment patterns and response rates of extracorporeal photopheresis (ECP) in CTCL patients.Methods A chart review was conducted in the United States of adults with CTCL who initiated ECP between January 1, 2017, and February 28, 2019, and received at least three months of ECP treatment as monotherapy or concomitant therapy. Clinical outcomes were collected quarterly for up to 18 months.Results The 52 patients were predominantly Caucasian. Half were male; median age was 69 years. Most patients had Sézary syndrome (50%) or mycosis fungoides (36.5%). Nearly 40% of patients had stage IV disease; 33% had lymph node involvement. Nineteen patients (36.5%) achieved response (>50% reduction in BSA affected); median time to response was 6.5 months. The percentage of patients rated as at least minimally improved was 59.5% at 6 months (N = 22), 75.0% at 9 months (N = 24), and 60.0% at 12 months (N = 15) after ECP initiation.Conclusions Despite the ECP treated population in this study being older and having more advanced-stage disease than recent trials, response rates were comparable. These real-world findings support ECP as an effective treatment option for CTCL patients.https://www.tandfonline.com/doi/10.1080/09546634.2024.2360568LymphomaT-Cellobservational studyphotopheresisreal-world data |
| spellingShingle | Michael Girardi Kacie Carlson Xingyue Huang Shelby L. Corman Patrick Edmundson Jordana Schmier Hrishikesh P. Kale Rutika Raina Francine Foss Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019 Journal of Dermatological Treatment Lymphoma T-Cell observational study photopheresis real-world data |
| title | Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019 |
| title_full | Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019 |
| title_fullStr | Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019 |
| title_full_unstemmed | Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019 |
| title_short | Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019 |
| title_sort | chart review study of real world clinical outcomes in patients with cutaneous t cell lymphoma treated with extracorporeal photopheresis in the us in 2017 2019 |
| topic | Lymphoma T-Cell observational study photopheresis real-world data |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2360568 |
| work_keys_str_mv | AT michaelgirardi chartreviewstudyofrealworldclinicaloutcomesinpatientswithcutaneoustcelllymphomatreatedwithextracorporealphotopheresisintheusin20172019 AT kaciecarlson chartreviewstudyofrealworldclinicaloutcomesinpatientswithcutaneoustcelllymphomatreatedwithextracorporealphotopheresisintheusin20172019 AT xingyuehuang chartreviewstudyofrealworldclinicaloutcomesinpatientswithcutaneoustcelllymphomatreatedwithextracorporealphotopheresisintheusin20172019 AT shelbylcorman chartreviewstudyofrealworldclinicaloutcomesinpatientswithcutaneoustcelllymphomatreatedwithextracorporealphotopheresisintheusin20172019 AT patrickedmundson chartreviewstudyofrealworldclinicaloutcomesinpatientswithcutaneoustcelllymphomatreatedwithextracorporealphotopheresisintheusin20172019 AT jordanaschmier chartreviewstudyofrealworldclinicaloutcomesinpatientswithcutaneoustcelllymphomatreatedwithextracorporealphotopheresisintheusin20172019 AT hrishikeshpkale chartreviewstudyofrealworldclinicaloutcomesinpatientswithcutaneoustcelllymphomatreatedwithextracorporealphotopheresisintheusin20172019 AT rutikaraina chartreviewstudyofrealworldclinicaloutcomesinpatientswithcutaneoustcelllymphomatreatedwithextracorporealphotopheresisintheusin20172019 AT francinefoss chartreviewstudyofrealworldclinicaloutcomesinpatientswithcutaneoustcelllymphomatreatedwithextracorporealphotopheresisintheusin20172019 |